Fig. 5: Anti-CTLA-4 and anti-TIGIT responses are mediated by CD8⁺ and NK cells in mouse mesenchymal cSCCs.

a Growth kinetics of IgG control, anti-PD-L1, and anti-PD-1-treated mesenchymal cSCCs (n = 10 per group). b–e Percentage of b CD8⁺ T cells, c NK cells, d GzmB⁺ CD8⁺ T cells, and e GzmB⁺ NK cells in IgG control, anti-PD-L1, and anti-PD-1-treated mesenchymal cSCCs (n = 10 per group). f, k Growth kinetics of IgG control, (f) anti-CTLA-4, anti-CTLA-4 + anti-CD8, and anti-CTLA-4 + anti-NK or (k) anti-TIGIT, anti-TIGIT + anti-CD8, and anti-TIGIT + anti-NK-treated mesenchymal cSCCs (n = 10 per group). For better visualization, this experiment has been separated into two graphs in which the IgG control group is the same. g–j, l, m Percentage of g, l CD8⁺ T cells, h, m NK cells, i GzmB⁺ CD8⁺ T cells, and j GzmB⁺ NK cells in the indicated mesenchymal cSCCs (n = 10 per group). n, o Percentage of GFP⁺EpCAM⁺ and GFP⁺EpCAM⁻ cancer cells in the indicated mesenchymal cSCCs (n = 10 per group). All data are represented as the mean ± SD, and n values indicate independent tumors. P values are determined by two-way ANOVA test (a, f, k) and one-way ANOVA with Dunnett’s multiple comparison test (b–e, g–j, l–o). ns > 0.05: not significant. See Supplementary Fig. 2 for the gating strategy (b–e, g–j, l–o). Source data are provided as a Source Data file.